Healius Ltd
HLS
Company Profile
Business description
Healius is one of Australia's pathology providers, operating a national network of laboratories and collection centres. Pathology generates nearly all group revenue, the majority of which comes from bulk-billed tests funded through the government's Medicare Benefits Schedule, with the remainder from public hospital contracts, private health funds, and specialty services, including genomics and veterinary pathology.
Contact
161 Castlereagh Street
Level 22
SydneyNSW2000
AUST: +61 294329400
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
Employees
8,000
Healius Ltd News & Analysis
stocks
Undervalued ASX share announces plan to create shareholder value
The market cheers update from the company.
stocks
Ask the analyst: Why have Healius shares struggled so much?
Shares in Australia's second biggest pathology operator have floundered in recent years. Shane Ponraj thinks better days could be ahead.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,903.50 | 44.30 | 0.50% |
| CAC 40 | 7,874.05 | 39.95 | 0.51% |
| DAX 40 | 25,441.35 | 187.14 | 0.74% |
| Dow JONES (US) | 51,267.90 | 90.94 | 0.18% |
| FTSE 100 | 10,577.25 | 79.31 | 0.76% |
| HKSE | 24,280.56 | 240.22 | 1.00% |
| NASDAQ | 27,477.31 | 286.45 | 1.05% |
| Nikkei 225 | 70,683.98 | 737.12 | 1.05% |
| NZX 50 Index | 13,700.12 | 1.10 | 0.01% |
| S&P 500 | 7,773.95 | 51.23 | 0.66% |
| S&P/ASX 200 | 8,735.70 | 49.30 | 0.57% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |